FIELD: biotechnology.
SUBSTANCE: disclosed are multispecific binding proteins which bind CD33, NKG2D receptor and CD16, as well as pharmaceutical compositions and therapeutic methods useful for treating cancer.
EFFECT: invention provides improved activation of NK-cells as a result of binding of two activating receptors.
17 cl, 57 dwg, 9 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYVALENT BINDING PROTEINS FOR ACTIVATION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC APPLICATION FOR TREATMENT OF MALIGNANT NEOPLASM | 2018 |
|
RU2809125C2 |
| BCMA, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2805254C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2826991C2 |
| POLYSPECIFIC BINDING PROTEINS TARGETING NKG2D, CD16 AND TROP2 | 2018 |
|
RU2820629C2 |
| POLY-SPECIFIC BINDING PROTEINS TARGETED TO CAIX, ANO1, MESOTHELIN, TROP2, CEA, AND CLAUDINE-18.2 | 2018 |
|
RU2792671C2 |
| MODIFIED NON-NATURAL NKG2D LIGANDS WHICH SELECTIVELY DELIVER ATTACHED HETEROLOGOUS MOLECULES TO NON-NATURAL NKG2D RECEPTORS ON CAR CELLS | 2020 |
|
RU2823728C2 |
| MODIFIED Α1-Α2 DOMAINS OF NON-NATURAL NKG2D LIGANDS THAT BIND TO NON-NATURAL NKG2D RECEPTORS | 2019 |
|
RU2815278C2 |
| NON-NATURAL NKG2D RECEPTORS WHICH DO NOT DIRECTLY TRANSMIT SIGNAL TO CELLS WITH WHICH THEY ARE BOUND | 2019 |
|
RU2832538C2 |
